
Wockhardt (WOCKPHARMA) Share Price Falls 2.97% as Stock Declines to Rs 2,001.90
Updated: 16 Sept 2026 • 11:15 am
Posted by:

Wockhardt Share Price moved lower today as Wockhardt slipped 2.97% to Rs 2,001.90, with market capitalisation at Rs 35,441.98 Cr. The move is relevant because the stock closed below its previous close of Rs 2,063.20 and stayed below the day’s open through much of the session. The supplied data confirms the price event, but it does not establish a company-specific catalyst. For investors tracking Wockhardt Share Price Today, the focus is on the day’s price action, the company’s valuation multiples, and how Wockhardt Stock News compares with its healthcare peers. Univest keeps the discussion factual so readers can connect today’s decline with the wider stock profile rather than speculate on an unverified trigger.
At a market level, the move also places Wockhardt Share Price News into a broader context of price action in the healthcare space. The company sits in the Large Cap category as supplied, and the session’s range shows that the stock traded between Rs 1,966.45 and Rs 2,075.00. Univest uses these verified figures to build a clear picture of what changed today and what remained unchanged.
Wockhardt (WOCKPHARMA) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,001.9 |
| Previous Close | Rs 2,063.2 |
| Today's Move | -Rs 61.30 (-2.97%) |
| Open | Rs 2,050.8 |
| High | Rs 2,075 |
| Low | Rs 1,966.45 |
| Turnover | Rs 10.7 crore |
| Market Capitalisation | Rs 35,441.98 crore |
| Market Cap Category | Large Cap |
Wockhardt Share Price Today ended at Rs 2,001.90, down Rs 61.30 or 2.97% from the previous close of Rs 2,063.20. The session opened at Rs 2,050.80, touched an intraday high of Rs 2,075.00 and a low of Rs 1,966.45. That means the day’s range was Rs 108.55, and the closing price finished below the open, the previous close and the intraday high. The reported turnover was Rs 10.7 Cr. The stock is classified as Large Cap in the supplied data, and its current market capitalisation stands at Rs 35,441.98 Cr.
What exactly happened today is straightforward from the record: Wockhardt Share Price declined during the session and closed near the middle of the day’s range rather than at the high. The data verifies the move, but it does not identify a specific news event or operating update as the cause. For readers searching Wockhardt Share Price Live, the most useful interpretation is that today’s decline should be read as a single-day price event within a larger listed-company profile. Univest tracks such moves by anchoring them in exact market data instead of speculation. The next part of the analysis moves from the day’s trade to the company’s valuation and profitability profile.
Wockhardt (WOCKPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 35,441.98 crore |
| P/E Ratio | 81.97x |
| P/B Ratio | 6.66x |
| ROE | 4.29% |
| ROCE | 6.79% |
| EPS | Rs 25.17 |
| Book Value Per Share | Rs 309.81 |
| Dividend Yield | 0% |
Wockhardt Share Price currently reflects a company with a market capitalisation of Rs 35,441.98 Cr, which places it in the Large Cap category as supplied. The valuation metrics are notable: the P/E ratio is 81.97 and the P/B ratio is 6.66. Those figures sit above the same-industry benchmark median of 31.74 for P/E and 3.02 for P/B, based on a benchmark scope of 200 companies in Pharmaceuticals & Drugs. That means Wockhardt is valued at a premium to the supplied industry median on both measures.
Profitability is more measured. ROE stands at 4.29%, while ROCE is 6.79%. Both are below the benchmark medians of 11.78% and 13.65% respectively, which indicates that the current valuation is not matched by stronger return metrics in the supplied comparison set. EPS is Rs 25.17, showing earnings attributable to each share, while book value is Rs 309.81 per share, indicating the accounting net worth behind each share. Dividend yield is 0, so no dividend yield is reflected in the supplied data. In Univest’s factual framing, these numbers do not explain today’s price fall, but they do show why Wockhardt Share Price News remains closely watched after a decline: the company combines a premium valuation with modest return ratios. The next section looks at how the ownership and comparison data should be read.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 81.97x |
| Benchmark Median P/E | 31.74x |
| Benchmark Average P/E | 47.98x |
| Benchmark P/E Range | 3.29x to 683.37x |
| Company P/B Ratio | 6.66x |
| Benchmark Median P/B | 3.02x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 4.29% |
| Benchmark Median ROE | 11.78% |
| Benchmark Average ROE | 11.19% |
| Company ROCE | 6.79% |
| Benchmark Median ROCE | 13.65% |
| Benchmark Average ROCE | 13.65% |
| Company Market Capitalisation | Rs 35,441.98 crore |
| Benchmark Median Market Cap | Rs 750.5 crore |
| Benchmark Average Market Cap | Rs 14,144.11 crore |
Wockhardt operates in Healthcare, specifically the Pharmaceuticals & Drugs industry. The same-industry benchmark in the supplied sector snapshot covers 200 companies, giving a useful base for comparison. Within that group, the company’s P/E of 81.97 is above the benchmark median of 31.74 and above the benchmark average of 47.98. Its P/B of 6.66 is also above the median of 3.02 and the average of 4.44. By contrast, ROE at 4.29% is below the benchmark median of 11.78%, and ROCE at 6.79% is below the benchmark median of 13.65%.
The market-cap benchmark also helps frame the company’s scale. The same-industry median market capitalisation is Rs 750.50 Cr, while the average is Rs 14,144.11 Cr; Wockhardt’s Rs 35,441.98 Cr is above both. That puts Wockhardt Share Price in a very different valuation bracket from the industry median company. Sector analysis on Univest is most useful when it pairs valuation with return metrics, because the figures show how the stock is priced relative to the healthcare universe without assuming why the market moved today. Investors tracking Wockhardt Stock Analysis can use the sector lens to see whether the company’s current ratios align with the wider industry profile.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,957.5 | 36.4 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,576 | 83.41 | 13.81 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,233.01 | 84.58 | 20.55 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,670.55 | 24.29 | 4.07 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,272.68 | 32.62 | 3.13 | 11.83 | 16 |
Wockhardt’s peer set shows a mixed picture when compared with other listed healthcare names. Its P/E of 81.97 is lower than Torrent Pharmaceuticals at 84.58 and Divi’s Laboratories at 83.41, but higher than Sun Pharmaceutical Industries at 36.40, Zydus Lifesciences at 24.29, and Cipla at 32.62. That places Wockhardt in the upper part of the peer valuation band, though not at the top.
On profitability, Wockhardt’s ROE of 4.29% and ROCE of 6.79% are below the supplied peer figures for the listed comparables, which range from 11.83% to 26.76% for ROE and from 16.00% to 21.51% for ROCE among the peers shown. On market capitalisation, Wockhardt’s Rs 35,441.98 Cr is below Sun Pharma, Divi’s, Torrent, Zydus Lifesciences and Cipla in the supplied peer set. For readers looking at Wockhardt Fundamental Analysis, the peer data shows that the stock trades on a richer multiple than some large peers while generating lower returns on equity and capital than the group in this comparison.
Why Investors Are Watching Wockhardt
- Wockhardt Share Price fell 2.97% today to Rs 2,001.90, compared with the previous close of Rs 2,063.20.
- The session opened at Rs 2,050.80, made a high of Rs 2,075.00 and a low of Rs 1,966.45.
- Market capitalisation stands at Rs 35,441.98 Cr and the stock is marked as Large Cap in the supplied data.
- P/E is 81.97 and P/B is 6.66, both above the same-industry medians of 31.74 and 3.02.
- ROE is 4.29% and ROCE is 6.79%, both below the same-industry medians of 11.78% and 13.65%.
About Wockhardt
Wockhardt operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied company profile is anchored in those classifications, which is enough to place the stock in its industry context without adding assumptions. For readers following Wockhardt Share Price and Wockhardt Stock News, the important point is that the company is evaluated here through its market data, sector setting and peer comparisons. Univest keeps the profile factual and concise, using only verified company, sector and industry references available in the data.
Track Wockhardt Share Price on Univest
Use Wockhardt (WOCKPHARMA) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Wockhardt falling today?
Ans. The supplied data confirms that Wockhardt Share Price fell 2.97% today to Rs 2,001.90, but it does not establish a company-specific catalyst. The session range and close explain the move factually.
What is Wockhardt Share Price Today?
Ans. Wockhardt Share Price Today is Rs 2,001.90. It is below the previous close of Rs 2,063.20 and also below the opening price of Rs 2,050.80, according to the supplied market data.
How is Wockhardt valued versus the healthcare sector?
Ans. Wockhardt’s P/E of 81.97 and P/B of 6.66 are above the same-industry medians of 31.74 and 3.02. Its ROE of 4.29% and ROCE of 6.79% are below the benchmark medians.
What do the profitability ratios say about Wockhardt?
Ans. Wockhardt reports ROE of 4.29% and ROCE of 6.79%. EPS is Rs 25.17 and book value is Rs 309.81 per share, while dividend yield is 0 in the supplied data.
How does Wockhardt compare with peers?
Ans. In the supplied peer set, Wockhardt’s P/E is below Torrent Pharmaceuticals and Divi’s Laboratories, but above Sun Pharma, Zydus Lifesciences and Cipla. Its ROE and ROCE are below the listed peers shown.
Recent Articles

Craftsman Automation (CRAFTSMAN) Share Price falls 2.65% today; stock news, valuation and sector context
16 September 2026

Multi Commodity Exchange Of India (MCX): MCX Share Price Falls 2.65%: What Dragged the Stock Today
16 September 2026

Laurus Labs (LAURUSLABS) Share Price Falls 2.67% to Rs 1,871.60
16 September 2026

NIACL Share Price Falls 2.8% as The New India Assurance Company (NIACL) Declines to Rs 180.6
16 September 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Craftsman Automation (CRAFTSMAN) Share Price falls 2.65% today; stock news, valuation and sector context
Multi Commodity Exchange Of India (MCX): MCX Share Price Falls 2.65%: What Dragged the Stock Today
Laurus Labs (LAURUSLABS) Share Price Falls 2.67% to Rs 1,871.60
NIACL Share Price Falls 2.8% as The New India Assurance Company (NIACL) Declines to Rs 180.6
Coforge (COFORGE) Share Price Falls 3.03% as Stock Slides to Rs 1,720.2

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





